Marengo Therapeutics Announces Promising Phase 2 Results for Breast Cancer Treatment at AACR 2026
Marengo Therapeutics, a clinical-stage biotechnology company, has reported encouraging interim results from its Phase 2a clinical trial of invikafusp alfa combined with TRODELVY® for treating metastatic breast cancer. The announcement was made at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The trial, known as STARt-002, is a collaboration with Gilead Sciences and focuses on patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer. The results showed confirmed complete responses in patients who had not responded to previous therapies. Additionally, Marengo unveiled its second precision T cell activator, IPN01203/STAR0501, developed in partnership with Ipsen, which is advancing into clinical trials. The company highlighted the safety profile of the treatment, which aligns with the known profiles of the individual agents, and the ongoing enrollment of patients across North America. 
